Q1 2023 Non-GAAP Operating Income

| 8 | AUSTEDO Continues to Reach More Patients Continued growth of AUSTEDO prescriptions AUSTEDO quarterly TRX 60,000 50,000 40,000 30,000 20,000 10,000 0 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Source: IQVIA US NPA Audit Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Revenue and TRX data is compared to Q1 2022 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 57,123 AustedoⓇ (deutetrabenazine) 6 mg, 9 mg, and 12 mg tablets U.S. Revenues $170 million Revenues Growth +10% TRX Growth +28% teva

View entire presentation